Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC

Posted on June 9, 2025
Post Views: 1

Lung CancerTarlatamab received accelerated approval for treatment of patients with previously treated small-cell lung cancer. It meaningfully improved overall survival compared with Chemotherapy in SCLC patients that progressed on or after initial platinum-based CTx. These observations are from the results of Phase 3 DeLLphi-304 clinical trial, published by investigators in Journal of Clinical Oncology and presnted at 2025 American Society of Clinical Oncology Annual Meeting in Chicago.

In phase 1 and 2 trials, tarlatamab demonstrated promising efficacy amomg SCLC patients. It was granted approval by FDA in 2024 for patients with extensive-Stage SCLC. In this latest study, findings showed that a median followup of 11.2 months for patients treated with tarlatamab and 11.7 months for those with chemotherapy treatment. Tarlatamab led to a median OS of 13.6 months in comparison to 8.3 months for chemotherapy.

In this DeLLphi trial, 509 patients with SCLC were enrolled who had disease progression after first-line platinum-based chemotherapy, with or withouorPD-(L)1 inhibitor. The patients were randomly assigned to receive tarlatamab or chemotherapy. Chemotherapy included topotecan, lurbinectedin or amrubicin. Tarlatamab improved the objective respinse rate, duration of response, PFS and OS. The results from this trial were published in The New England Journal of Medicine as well.

study author Charles Rudin said, “Taking the efficacy and safety data together, I think these data clearly support tarlatamab as a preferable therapy for patients in the second-line setting for small-cell lung cancer. Beyond redefining the standard of care for these patients, this study also establishes a new paradigm for the use of bispecific T-cell engager immunotherapies in our patients with lung cancer.”

The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.

Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,325)
  • Lung Cancer: Symptoms and Treatment (5,658)
  • What is Non-Small-Cell Lung Cancer? (5,557)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC June 9, 2025
  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d